Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus
- 1 July 2021
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 150, 65-68
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
- Janssen Pharmaceutica
- Pfizer
This publication has 23 references indexed in Scilit:
- A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness AnalysesValue in Health, 2018
- Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular riskJournal of Diabetes and its Complications, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsCirculation, 2017
- Number needed to treat (NNT) in clinical literature: an appraisalBMC Medicine, 2017
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trialEuropean Heart Journal, 2016
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task ForceValue in Health, 2013
- CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized TrialsAnnals of Internal Medicine, 2010
- Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditionsJournal of Clinical Epidemiology, 2006
- The Incidence of Congestive Heart Failure in Type 2 DiabetesDiabetes Care, 2004